OVID (Ovid Therapeutics Inc) Net earnings per share for the last 12 months

Ovid Therapeutics Inc. (OVID) develops drugs for the treatment of rare epilepsies using a non-sedating small molecule platform. The annual net income per share trend helps assess the issuer's margins, while the value of -0.18 shows the most recent figure. Development relies on automated substance synthesis, and the environmental profile is limited to compliance with laboratory safety standards and digital accounting.
Analytical breakdowns and data insights for company Ovid Therapeutics Inc. (OVID)

Trailing 12-month net earnings per share is calculated as the ratio of the final financial result to the total number of securities. This metric determines the actual equity return by excluding the impact of one-time write-offs. By analyzing this 12-month EPS chart, an investor tracks capital resilience against external shocks. For Ovid Therapeutics Inc. (OVID), this indicator reflects the cost of R&D investments in epilepsy drugs. Negative values here confirm the active development stage of CNS medications.